Joffe R T
Department of Psychiatry, McMaster University, Hamilton, Ontario.
J Clin Psychiatry. 1998;59 Suppl 5:26-9; discussion 30-1.
Despite methodological flaws that limit conclusions, a considerable database documents the efficacy of triiodothyronine (T3) as an augmentation strategy for response to various classes of antidepressants. One study suggests that T3 and lithium are of comparable efficacy in antidepressant nonresponders. No clear biochemical or clinical predictors of preferential response to T3 have been found. The role of T3 augmentation requires further evaluation, especially with regard to dose and duration.
尽管存在限制结论的方法学缺陷,但大量数据库记录了三碘甲状腺原氨酸(T3)作为增强各类抗抑郁药反应策略的疗效。一项研究表明,在抗抑郁药无反应者中,T3和锂的疗效相当。尚未发现对T3优先反应的明确生化或临床预测指标。T3增强疗法的作用需要进一步评估,特别是在剂量和疗程方面。